Cargando…
Clinical Trial Considerations in Neuro-oncology
Clinical trials play a critical role in discovering new treatments, but the path to regulatory approval can be cumbersome and time consuming. Efforts to increase the efficiency and interpretability of clinical trials within the neuro-oncology community have focused on standardization of response ass...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252693/ https://www.ncbi.nlm.nih.gov/pubmed/34213625 http://dx.doi.org/10.1007/s11864-021-00875-8 |
| _version_ | 1783717352599191552 |
|---|---|
| author | Lee, Eudocia Q. |
| author_facet | Lee, Eudocia Q. |
| author_sort | Lee, Eudocia Q. |
| collection | PubMed |
| description | Clinical trials play a critical role in discovering new treatments, but the path to regulatory approval can be cumbersome and time consuming. Efforts to increase the efficiency and interpretability of clinical trials within the neuro-oncology community have focused on standardization of response assessment, development of consensus guidelines for clinical trial conduct, decentralization of clinical trials, removal of barriers to clinical trial accrual, and re-examination of patient eligibility criteria. |
| format | Online Article Text |
| id | pubmed-8252693 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82526932021-07-02 Clinical Trial Considerations in Neuro-oncology Lee, Eudocia Q. Curr Treat Options Oncol Neuro-oncology (GJ Lesser, Section Editor). Clinical trials play a critical role in discovering new treatments, but the path to regulatory approval can be cumbersome and time consuming. Efforts to increase the efficiency and interpretability of clinical trials within the neuro-oncology community have focused on standardization of response assessment, development of consensus guidelines for clinical trial conduct, decentralization of clinical trials, removal of barriers to clinical trial accrual, and re-examination of patient eligibility criteria. Springer US 2021-07-02 2021 /pmc/articles/PMC8252693/ /pubmed/34213625 http://dx.doi.org/10.1007/s11864-021-00875-8 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Neuro-oncology (GJ Lesser, Section Editor). Lee, Eudocia Q. Clinical Trial Considerations in Neuro-oncology |
| title | Clinical Trial Considerations in Neuro-oncology |
| title_full | Clinical Trial Considerations in Neuro-oncology |
| title_fullStr | Clinical Trial Considerations in Neuro-oncology |
| title_full_unstemmed | Clinical Trial Considerations in Neuro-oncology |
| title_short | Clinical Trial Considerations in Neuro-oncology |
| title_sort | clinical trial considerations in neuro-oncology |
| topic | Neuro-oncology (GJ Lesser, Section Editor). |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252693/ https://www.ncbi.nlm.nih.gov/pubmed/34213625 http://dx.doi.org/10.1007/s11864-021-00875-8 |
| work_keys_str_mv | AT leeeudociaq clinicaltrialconsiderationsinneurooncology |